Organisation paid for research Program year 2025 Source: CMS Open Payments

Ormond Beach Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,443,804

186 payments

Through program year 2025, Ormond Beach Clinical Research is reported as receiving $1,443,804 in research payments, across 186 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $315,610 22
2024 Research $359,735 14
2023 Research $402,243 18
2022 Research $156,549 49
2021 Research $33,563 44
2020 Research $72,088 25
2019 Research $104,017 14

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca UK Limited $659,943 6 payments
  2. AstraZeneca Pharmaceuticals LP $521,323 25 payments
  3. Novartis Pharmaceuticals Corporation $81,735 8 payments
  4. Esperion Therapeutics, Inc. $58,817 103 payments
  5. Moderna TX, Inc. $26,580 9 payments
  6. Novo Nordisk AS $23,885 8 payments
  7. Amgen Inc. $15,493 2 payments
  8. Mylan Specialty L.P. $14,202 8 payments
  9. Genentech, Inc. $12,500 3 payments
  10. GlaxoSmithKline, LLC. $11,125 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $418,243 3 payments
  2. A Phase II Randomized Openlabel Multicenter Doseranging Study in Adults and Pediatric Individuals 2265 12 years of Age to Assess the Safety Immunogenicity Pharmacokinetics and Pharmacodynamics of AZD7442 a Combination Product of Two Monoclonal Antibodies Tixagevimab and Cilgavimab for Pre-exposure Prophylaxis of COVID19 $241,700 3 payments
  3. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) $144,211 3 payments
  4. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $117,244 2 payments
  5. Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneously SC in adult participants with symptomatic COPD and history of 2 moderate or 1 severe exacerbation of COPD in the previous 12 months $101,138 5 payments
  6. An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) $73,163 5 payments
  7. A 24 Week Multicenter Double Blind Placebo Controlled Dose Ranging Study to Investigate the Efficacy and Safety of Oral Qbw251 in COPD Patients on Triple Therapy (Laba/Lama/Ics) $66,224 4 payments
  8. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $58,817 103 payments
  9. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations $37,110 3 payments
  10. A 24 Week Multicenter Randomized Double blind Parallel Group Placebocontrolled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure $29,799 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record